Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DYAI Dyadic International	$0.85 +8.8%	$0.96	$0.71 ▼ $2.20	$30.76M	0.89	132,437 shs	253,904 shs
KZIA Novogen	$7.71 +5.5%	$8.38	$2.86 ▼ $39.05	$7.77M	2.64	67,004 shs	4,338 shs
MAAQ Mana Capital Acquisition	$3.68 +1.1%	$3.92	$5.35 ▼ $10.25	$29.90M	N/A	33,075 shs	19,903 shs
MDCX Medicus Pharma	$2.22 -9.4%	$2.67	$1.80 ▼ $8.94	$39.55M	N/A	411,232 shs	590,547 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DYAI Dyadic International	0.00%	+13.59%	-24.11%	-14.64%	-35.61%
KZIA Novogen	0.00%	-4.05%	-22.64%	+115.22%	-57.92%
MAAQ Mana Capital Acquisition	+1.10%	+1.38%	-16.55%	-6.84%	+717.96%
MDCX Medicus Pharma	0.00%	+13.27%	-26.49%	-69.55%	+221,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DYAI Dyadic International	2.7743 of 5 stars	3.5	5.0	0.0	0.0	0.0	3.3	0.0
KZIA Novogen	3.1687 of 5 stars	3.8	5.0	0.0	0.0	0.0	0.0	0.0
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	1.8682 of 5 stars	3.8	0.0	0.0	0.0	2.2	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DYAI Dyadic International	3.00	Buy	$6.00	605.88% Upside
KZIA Novogen	3.50	Strong Buy	$14.00	81.70% Upside
MAAQ Mana Capital Acquisition	0.00	N/A	N/A	N/A
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	958.56% Upside

Current Analyst Ratings Breakdown

Latest KZIA, MAAQ, MDCX, and DYAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
8/13/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/10/2025	KZIA Novogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy ➝ Strong-Buy	$13.00
7/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/1/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/23/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/11/2025	KZIA Novogen	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
6/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/29/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DYAI Dyadic International	$3.42M	8.99	N/A	N/A	($0.01) per share	-85.00
KZIA Novogen	$1.51M	5.15	N/A	N/A	($9.87) per share	-0.78
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.18 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DYAI Dyadic International	-$5.81M	-$0.19	N/A	N/A	N/A	-134.84%	-355.39%	-60.66%	11/11/2025 (Estimated)
KZIA Novogen	-$17.56M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	-$11.16M	-$1.34	N/A	N/A	N/A	N/A	-549.30%	-228.06%	N/A

Latest KZIA, MAAQ, MDCX, and DYAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	DYAI Dyadic International	-$0.06	-$0.06	N/A	-$0.06	$0.60 million	$0.97 million
8/11/2025	Q2 2025	MDCX Medicus Pharma	-$0.39	-$0.43	-$0.04	-$0.43	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DYAI Dyadic International	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	N/A	N/A	N/A	N/A	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DYAI Dyadic International	5.40	2.02	2.02
KZIA Novogen	N/A	0.21	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	1.29	1.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DYAI Dyadic International	27.95%
KZIA Novogen	30.89%
MAAQ Mana Capital Acquisition	68.44%
MDCX Medicus Pharma	N/A

Insider Ownership

Company	Insider Ownership
DYAI Dyadic International	29.50%
KZIA Novogen	1.00%
MAAQ Mana Capital Acquisition	N/A
MDCX Medicus Pharma	11.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DYAI Dyadic International	7	36.19 million	25.51 million	Optionable
KZIA Novogen	12	1.01 million	997,000	Optionable
MAAQ Mana Capital Acquisition	1	8.13 million	N/A	Not Optionable
MDCX Medicus Pharma	N/A	17.82 million	15.82 million	N/A

KZIA, MAAQ, MDCX, and DYAI Headlines

Recent News About These Companies

Medicus Pharma Completes Equity Sales to Yorkville

August 22 at 8:21 PM | msn.com

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of ...

August 21 at 9:33 AM | finance.yahoo.com

Medicus Pharma Advances D-MNA Clinical Program and Expands Strategic Partnerships

August 21 at 8:51 AM | tipranks.com

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

August 21 at 7:30 AM | newsfilecorp.comN

Biotech at a Pivotal Moment: Four Stocks Defining The Transformation (MDCX, IOBT, INSM, RNA)

August 20, 2025 | theglobeandmail.com

Biotech’s Big Comeback: 4 Stocks Poised to Ride the Resurgence (MDCX, ARVN, RYTM, ENTA)

August 19, 2025 | theglobeandmail.com

Q3 EPS Forecast for Medicus Pharma Decreased by Analyst

August 19, 2025 | americanbankingnews.com

Medicus Pharma Ltd to Acquire Antev Ltd in Strategic Expansion Move

August 7, 2025 | theglobeandmail.com

Medicus Pharma Seeks FDA Fast-Track Approval for Innovative Skin Cancer Treatment

August 7, 2025 | theglobeandmail.com

Medicus Pharma announces MoU with HelixNano

August 4, 2025 | thepharmaletter.comT

Medicus Pharma and HelixNano agree outline deal to develop heat-stable vaccines

August 4, 2025 | proactiveinvestors.com

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

August 4, 2025 | newsfilecorp.comN

Medicus Pharma Appoints Deloitte for Licensing Deal

July 30, 2025 | tipranks.com

Medicus Pharma Ltd. Strengthens Board with New Appointments

July 23, 2025 | tipranks.com

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

July 23, 2025 | newsfilecorp.comN

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to ...

July 23, 2025 | finanznachrichten.de

Medicus Pharma Ltd.: Medicus Pharma Ltd Announces a Definitive ...

July 23, 2025 | finanznachrichten.de

Medicus Pharma Ltd. Expands Clinical Trials and Announces Strategic Acquisition

July 21, 2025 | tipranks.com

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

July 21, 2025 | newsfilecorp.comN

Medicus Pharma Ltd. (NASDAQ:MDCX): Novel Pipeline Presents Unique Opportunity To Capitalize On Rare Disease Market Worth Over $15 Billion

July 16, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA, MAAQ, MDCX, and DYAI Company Descriptions

Dyadic International NASDAQ:DYAI

$0.85 +0.07 (+8.83%)

As of 08/22/2025 04:00 PM Eastern

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Novogen NASDAQ:KZIA

$7.70 +0.41 (+5.55%)

Closing price 08/22/2025 03:58 PM Eastern

Extended Trading

$7.70 0.00 (0.00%)

As of 08/22/2025 07:52 PM Eastern

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Mana Capital Acquisition NASDAQ:MAAQ

$3.68 +0.04 (+1.10%)

As of 08/22/2025

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.

Medicus Pharma NASDAQ:MDCX

$2.22 -0.23 (-9.39%)

As of 08/22/2025 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time